Sodium Nucroseospermate (Natrii nucleospermas)

Pharmacodynamics Pharmacokinetics Indications Carefully Contraindications Dosing and Administration Side effects
Read on
Clinical and pharmacological group: & nbsp

Stimulators of hematopoiesis

Included in the formulation
  • Sodium Nucroseospermate
    solution w / m PC 
    APOLLON, CJSC     Russia
    • АТХ:

    L.03.A   Cytokines and immunomodulators

    Pharmacodynamics:

    The drug stimulates hemopoiesis, affects the migration, proliferation and differentiation of colony-forming units, affecting all levels of hematopoiesis. The drug is actively built into cellular structures, participating in cellular metabolism. Has immunomodulatory effect, activates killer cells, potentiates the formation of antibodies. Accelerates granulocytopoiesis in the stage of promyelocytes and myelocytes, increases the neutrophil maturation index. Restores hematologic parameters, reduced as a result of chemotherapy.

    Pharmacokinetics:

    The time to reach the maximum concentration with a single subcutaneous or intramuscular injection is 0.5 hours, with rectal administration - 5 hours. The half-life with subcutaneous and intramuscular injection is 63-69 hours. The main pathway of sodium transport of nucleospermate for all methods of administration is endolymphatic. The bone marrow, lymph nodes, spleen, thymus and kidneys have the greatest tropism. The drug penetrates the blood-brain barrier. The half-life is 63-69 hours Excreted by the kidneys and gastrointestinal tract.

    With intramuscular introduction, about 50% of the drug is excreted by the kidneys and 12.5% ​​intestine, with subcutaneous injection - 37% and 3%, with rectal administration - 2.5% and 61.5%, respectively.

    Indications:

    Injection: leukopenia in radiation and cytostatic therapy (prevention and treatment) in adults and children over 3 years of age.

    Solution for rectal administration: HIV-infection at different stages of the disease (as an immunomodulator in combination therapy with antiviral drugs).

    ICD-10

    I.B20-B24   Disease caused by the human immunodeficiency virus [HIV]

    III.D70-D77.D70   Agranulocytosis

    XX.Y40-Y59.Y43.1   Antineoplastic antimetabolites

    XX.Y40-Y59.Y43.2   Antineoplastic natural preparations

    XX.Y40-Y59.Y43.3   Other antineoplastic agents

    XX.Y83-Y84.Y84.2   Radiological procedure and radiation therapy

    Contraindications:
    • Pregnancy.
    • Lactation.
    • Age to 3 years.
    • Hypersensitivity.
    • Diseases of the liver and kidneys, pancreas, gastrointestinal tract.
    • Violation of cerebral circulation.
    • Decompensated chronic heart failure.
    Carefully:

    Myeloid premalignant disease.

    Pregnancy and lactation:

    Category FDA not determined.The drug is contraindicated in pregnancy and lactation.

    Dosing and Administration:

    The single dose is 0.075 g, the maximum daily dose is 10 ml, the maximum exchange dose is 150 ml.

    Subcutaneously, intramuscularly slowly (for 1.5-2 min, pre-heated to body temperature), adults and children over 3 years old - at a rate of 42 mg / m2 at day (not less than 66 mg in day regardless of the body surface and age of the patient), the maximum single dose is 150 mg.

    For neutropenia: adults - 5-10 ml of 1.5% solution once a day, treatment course 5-10 days. Children 5 ml once a day, treatment course 1-4 days.

    In case of HIV infection: 25 ml 1-1.5% solution 2 times a day 2 times a week.

    The course of treatment is 1-6 months.

    Side effects:

    Raise body temperature to subfebrile, hyperemia, tenderness at the injection site.

    When rectal administration, side effects were not identified.

    Overdose:

    Not described, treatment is symptomatic.

    Interaction:

    Anticoagulants potentiate the effect of the drug.

    Special instructions:

    Impact on the ability to drive vehicles and manage mechanisms.

    Not found.

    Instructions
    Up